Recent Deadly Infection Scares at Schools Prompt Request for Information on

the MRSA Drug Market

October 22, 2007 - Waltham, Massachusetts - Recent deadly infection scares at national schools have prompted many calls into Decision Resources analyst Danielle Drayton, Ph.D. Dr. Drayton is an expert on the MRSA drug market and is available to assist in news stories that are looking for background on the drugs and players in the market.

  Dr. Drayton can discuss the following:   -- MRSA is one of the fastest growing segments of the antibiotic market.      Expected to increase by 40% over the next ten years from 2006 level.   -- MRSA had been largely generic in the past, but Pfizer's Zyvox and      Cubist/Novartis' Cubicin is making inroads in this market, and up to 6      new therapies can potentially launch in the next 5 years. However, all      the new drugs are administered parenterally, so there is still plenty      of room for oral MRSA antibiotics.   -- The infection that has been in the news was mostly a pathogen found in      the hospital setting, but community acquired MRSA has become an      increasingly important problem, potentially can become much worse if      community strains gain more resistance. Similarly, hospital strains are      becoming less susceptible to vancomycin, raising the alarm for new      therapies.  

Dr. Drayton is working on an upcoming MRSA report that will be published and available soon. To speak with her, please contact Liz Marshall at 781-296-2563 or

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   781-296-2563 

PRNewswire -- Oct. 22

SOURCE: Decision Resources, Inc.

Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011

View Now